Multiple Myeloma: New Treatment Combinations

We are studying a combination of new medications for people with newly diagnosed multiple myeloma who can undergo a transplant. The goal is to evaluate their safety and effectiveness in improving treatment outcomes.

Efficacy phase (II)No Placebo Partially Remote Investigational Medicines Oral InjectionHematologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Darzalex

Darzalex is a medicine used to treat multiple myeloma, a type of blood cancer.

Lenalidomid Al

Lenalidomid Al is a medicine used to treat certain blood cancers and bone marrow disorders.

Lenalidomid Hexal

Lenalidomid Hexal is a cancer medicine used to treat certain blood cancers and bone marrow disorders.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Betamethasone Sodium Phosphate

Betamethasone sodium phosphate is a corticosteroid substance that reduces inflammation and suppresses immune reactions in allergic, inflammatory, and skin conditions.

Bortezomib

Bortezomib is a substance that blocks cellular protein breakdown to treat certain blood cancers, including multiple myeloma.

Daratumumab

Daratumumab is a substance that helps treat multiple myeloma, a blood cancer, by directing the immune system to attack the cancerous plasma cells.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Jnj-64407564

Jnj-79635322

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

7,5 Mg Stada

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Klinikum Chemnitz gGmbH

Klinik für Innere Medizin III

Chemnitz, Germany

Universitaetsklinikum Carl Gustav Carus Dresden an der Technischen Universitaet Dresden AöR

Medizinische Klinik und Poliklinik I

Dresden, Germany

Universitaetsklinikum Duesseldorf AöR

Klinik für Hämatologie, Onkologie und klinische Immunologie

Düsseldorf, Germany

Sponsor: Universitaetsklinikum Heidelberg AöR

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.